Journal article

Phenylbutazone dose response data in patients with rheumatoid artritis.

WC Dick, PM Brooks, WW Buchanan, PD Fowler

J Int Med Res | Published : 1977

Abstract

90 patients with seropositive erosive rheumatoid arthritis were given either 50 mg or 100 mg phenylbutazone t.i.d. for 2 weeks and clinically assessed. Although the serum concentration of phenylbutazone was on the whole higher in the high-dose group, the objective parameters fluctuated so widely that no correlation to dose could be established. Pain relief was clearly better with the higher dose regime. As there are reports of possible serious side-effects of phenylbutazone it is important that patients should be given individual minimal effective doses of this drug.